ERBB2 and neoplasm: Key trials of targeted therapies include TOGA, in which trastuzumab, a monoclonal antibody that targets HER2, in combination with chemotherapy improved outcomes compared with chemotherapy alone in patients with HER2+ tumours; and REGARD and RAINBOW, in which the vascular endothelial growth factor (VEGF) receptor inhibitor ramucirumab was beneficial as a single agent or combined with paclitaxel, respectively [77–79].